Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792780 | 1.00 | CYP2C19 (0.39) | CYP2C19SMN1; SMN2MMEMAPK1LTA4H | |
| SCHEMBL6799001 | 0.84 | CYP4F2 (0.43) | SMN1; SMN2MMEMAPK1 | |
| SCHEMBL6798996 | 0.84 | CYP4F2 (0.43) | SMN1; SMN2MMEMAPK1 | |
| SCHEMBL8595523 | 0.81 | CYP2C19 (0.41) | CYP2C19SMN1; SMN2MMEMAPK1LTA4H | |
| SCHEMBL15592837 | 0.77 | CYP2C19 (0.35) | CYP2C19SMN1; SMN2MMEMAPK1 | |
| SCHEMBL9543283 | 0.73 | CYP2C19 (0.50) | CYP2C19MMEMAPK1 | |
| SCHEMBL16058545 | 0.70 | CYP2C19 (0.50) | CYP2C19MMELTA4H | |
| SCHEMBL4697171 | 0.69 | CYP2C19 (0.39) | CYP2C19MME | |
| SCHEMBL19091308 | 0.69 | CYP2C19 (0.39) | CYP2C19MMELTA4H | |
| Bromide SCHEMBL16057408 | 0.69 | CYP2C19 (0.48) | CYP2C19MMELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | APP, BACE1, APH1A | CYP2C19 1748/4885SMN1; SMN2 721/4885MME 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.